drugset
drugset / Trial / NCT04203043

The Prevstain Trial

NCT04203043 ↗

Phase 2 Unknown 338 enrolled University of Sao Paulo General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate whether oral supplementation with Pycnogenol (Flebon®) can interfere with skin hyperpigmentation after polidocanol foam sclerotherapy in patients with mild to moderate chronic venous insufficiency (CEAP C2 and C3) compared with the use of Placebo.

Timeline

Start
2020-02-28
Primary completion
2020-03-28
Completion
2021-12-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator MARITIME PINE Traditional medicine (herbal / TCM) — Oral

Indications

varicose disease